Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim

Inclusion Criteria

Age 18 years or over
Eastern cooperative oncology group (ECOG) performance status 0-2
Female with newly diagnosed, not previously treated with chemotherapy, stage I-III breast cancer
Planning to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy
Medically eligible to safely receive adjuvant or neoadjuvant chemotherapy and pegfilgrastim as determined by the investigator
Planning to receive prophylaxis with pegfilgrastim starting in the first cycle and continuing throughout each chemotherapy cycle of the study period
Has provided informed consent
Able to understand the content of the DVD material, in investigator's opinion
Able to read and understand English

Exclusion Criteria

Planning to receive weekly chemotherapy

Chronic use of oral non-steroidal anti-inflammatory drugs (NSAIDs) or oral antihistamines with the following exception:

- Chronic oral aspirin use for cardiovascular-related indications

Ongoing chronic pain, or other painful conditions requiring treatment (including immediate post-operative treatment of surgical or procedural-associated pain) as determined by the investigator
Chronic oral steroid use. Premedication related to the administration of taxanes, and use of anti-emetics is allowed, per usual clinical practice.
Prior chemotherapy treatment for cancer within 5 years of current breast cancer diagnosis
Prior use of granulocyte-colony stimulating factor (G-CSF)
Currently enrolled in, or less than 30 days since ending, another clinical trial which includes language directing G-CSF (filgrastim, pegfilgrastim, other) or granulocyte-macrophage colony stimulating factor (GM-CSF) (sargramostim) use
Currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes a blinded treatment or blinded treatment arm (whether or not the subject is randomized to the blinded arm)
Currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes the use of any agent not currently considered to be standard therapy for the adjuvant or neoadjuvant treatment of stage I-III breast cancer based on National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Breast Cancer
Currently enrolled in, or less than 30 days since ending, any pain intervention study